MRK Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Merck & Co Inc (MRK) is a good buy for a beginner investor with a long-term investment strategy and $50,000-$100,000 available. The stock has strong positive catalysts, favorable analyst ratings, and a solid growth outlook despite some near-term challenges. The SwingMax signal further supports a buy decision.
The MACD histogram is positive and expanding, indicating bullish momentum. RSI is neutral at 69.7, and moving averages are converging, suggesting no immediate overbought or oversold conditions. The stock is trading near its R1 resistance level of 119.111, with potential upside towards R2 at 120.858.
Promising results from the mRNA-4157 cancer vaccine developed with Moderna.
Acquisition of Terns Pharmaceuticals strengthens the blood cancer pipeline.
Analysts project strong near-term launches and Phase 3 readouts driving growth.
SwingMax signal supports a buy-low, sell-high opportunity.
Insider selling has increased significantly by 2945.40% over the last month.
Recent financial performance shows a decline in net income (-20.84% YoY) and EPS (-19.59% YoY).
In Q4 2025, revenue increased by 4.97% YoY to $16.4 billion. However, net income dropped by 20.84% YoY to $2.96 billion, and EPS declined by 19.59% YoY to 1.19. Gross margin also decreased slightly to 74.15%.
Analysts are generally positive on MRK, with multiple firms raising price targets recently. Citi raised its target to $125, Wells Fargo to $150, and RBC to $142, among others. The consensus highlights confidence in Merck's ability to navigate Keytruda's patent cliff and capitalize on its robust pipeline.
